Mycobacterium tuberculosis multi-epitope antigen (Mtb-MEA)

The Mycobacterium tuberculosis multi-epitope antigen is a synthetic, recombinant protein designed to serve as a vaccine candidate by incorporating multiple immunodominant epitopes from various Mycobacterium tuberculosis (Mtb) proteins (Scientific Reports, 2021). These constructs typically fuse segments from well-characterized antigens such as Ag85B, ESAT-6, CFP-10, and HspX into a single chimeric molecule to elicit a broad and robust immune response (Frontiers in Immunology, 2020). By combining epitopes that target different stages of the Mtb life cycle—including active replication and latency—these antigens aim to provide superior protection compared to single-antigen vaccines (Nature Communications, 2019). In a clinical context, these antigens are not traditional drug targets like receptors or enzymes; rather, they are the active components of subunit vaccines, such as the M72/AS01E candidate, that interact with the host's immune system (New England Journal of Medicine, 2018). Upon administration, the antigen is processed by antigen-presenting cells and presented to T-lymphocytes via MHC molecules, triggering the release of protective cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) (PubMed, 2022). This process establishes immunological memory, which is critical for preventing the progression from latent infection to active tuberculosis disease (The Lancet, 2019).

Other names

Multi-epitope vaccineMtb chimeric antigenPolyepitope fusion proteinMtb subunit vaccine candidateM72H56ID93

Induction of adaptive immunity through the presentation of multiple Mycobacterium tuberculosis epitopes to T-cells via MHC molecules, resulting in the production of protective Th1 cytokines.